{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:41:38Z","timestamp":1787060498541,"version":"build-2736575974"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Noonan syndrome and related disorders (RASopathies) affect ~1 in 2000 individuals and are associated with a wide range of phenotypic manifestations. It is highly likely that pediatricians and other pediatric subspecialists will encounter multiple patients with these diagnoses in their clinical practice. It is important that pediatric providers recognize common diagnostic features and are informed regarding recent advances in diagnosis and emerging treatment options for patients with these conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Major themes of research articles published about RASopathies in the past 18\u200amonths include the utilization of pathway targeted drugs such as trametinib for treatment-refractory cardiac and lymphatic manifestations, emerging genotype\u2013phenotype correlations, and detailed characterization of neurologic manifestations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The potential for pathway targeted therapy, with increasing reported use of trametinib for severe cardiac and lymphatic manifestations of RASopathies, exemplifies the importance of recognizing RASopathy diagnoses and of clearly defining natural history and treatment endpoints. Further refinement of genotype\u2013phenotype correlations and the phenotypic spectrum, particularly the delineation of neurologic manifestations clinically and radiographically, are likely to be areas of significant knowledge growth in upcoming years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mop.0000000000001524","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:00:09Z","timestamp":1763035209000},"page":"126-132","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Current opinions on Noonan syndrome and RASopathies"],"prefix":"10.1097","volume":"38","author":[{"given":"Kathryn Nicole","family":"Weaver","sequence":"first","affiliation":[{"name":"The Heart Institute, Cincinnati Children's Hospital Medical Center"},{"name":"Division of Human Genetics, Cincinnati Children's Hospital Medical Center"},{"name":"University of Cincinnati College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E.","family":"Prada","sequence":"additional","affiliation":[{"name":"Edwards Family Division of Genetics and Rare Diseases, Ann & Robert H. Lurie Children's Hospital of Chicago"},{"name":"Northwestern University Feinberg School of Medicine, Evanston, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"R1-20251226","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ng772","article-title":"Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome","volume":"29","author":"Tartaglia","year":"2001","journal-title":"Nat Genet"},{"key":"R2-20251226","doi-asserted-by":"crossref","first-page":"103430","DOI":"10.1016\/j.gimo.2025.103430","article-title":"Updated ACMG\/AMP specifications for variant interpretation and gene curations from the ClinGen RASopathy expert panels","volume":"3","author":"Wilcox","year":"2025","journal-title":"Genet Med Open"},{"key":"R3-20251226","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijcard.2017.07.068","article-title":"Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results","volume":"245","author":"Calcagni","year":"2017","journal-title":"Int J Cardiol"},{"key":"R4-20251226","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/ajmg.a.38854","article-title":"Nonreentrant atrial tachycardia occurs independently of hypertrophic cardiomyopathy in RASopathy patients","volume":"176","author":"Levin","year":"2018","journal-title":"Am J Med Genet A"},{"key":"R5-20251226","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1002\/ajmg.a.62955","article-title":"Lymphatic anomalies during lifetime in patients with Noonan syndrome: retrospective cohort study","volume":"188","author":"Swarts","year":"2022","journal-title":"Am J Med Genet A"},{"key":"R6-20251226","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00247-018-04337-6","article-title":"Imaging of central lymphatic abnormalities in Noonan syndrome","volume":"49","author":"Biko","year":"2019","journal-title":"Pediatr Radiol"},{"key":"R7-20251226","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.jacc.2019.01.066","article-title":"Hypertrophic cardiomyopathy in noonan syndrome treated by MEK-inhibition","volume":"73","author":"Andelfinger","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R8-20251226","doi-asserted-by":"crossref","first-page":"e20200167","DOI":"10.1542\/peds.2020-0167","article-title":"Severe lymphatic disorder resolved with MEK inhibition in a patient with Noonan syndrome and SOS1 mutation","volume":"146","author":"Dori","year":"2020","journal-title":"Pediatrics"},{"key":"R9-20251226","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3390\/genes13091503","article-title":"Severe lymphatic disorder and multifocal atrial tachycardia treated with trametinib in a patient with Noonan syndrome and SOS1 mutation","volume":"13","author":"Lioncino","year":"2022","journal-title":"Genes (Basel)"},{"key":"R10-20251226","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jacbts.2024.10.002","article-title":"Impact of MEK inhibition on childhood RASopathy-associated hypertrophic cardiomyopathy","volume":"10","author":"Wolf","year":"2025","journal-title":"JACC Basic Transl Sci"},{"key":"R11-20251226","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2023.02.010","article-title":"MEK inhibition improves cardiomyopathy in Costello syndrome","volume":"81","author":"Geddes","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"R12-20251226","doi-asserted-by":"crossref","first-page":"ytad190","DOI":"10.1093\/ehjcr\/ytad190","article-title":"Successful treatment of refractory chylothorax with MEK inhibitor trametinib in a child with Noonan syndrome: case report","volume":"7","author":"Hribernik","year":"2023","journal-title":"Eur Heart J Case Rep"},{"key":"R13-20251226","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1017\/S1047951124036126","article-title":"Novel use of trametinib for treatment of atrial arrhythmia in absence of cardiomyopathy in a patient with Costello syndrome","volume":"34","author":"Kato","year":"2024","journal-title":"Cardiol Young"},{"key":"R14-20251226","doi-asserted-by":"crossref","first-page":"102379","DOI":"10.1016\/j.jaccas.2024.102379","article-title":"Treatment of RAF1-related obstructive hypertrophic cardiomyopathy by MEK inhibition using trametinib","volume":"29","author":"Kiamanesh","year":"2024","journal-title":"JACC Case Rep"},{"key":"R15-20251226","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s12098-024-05305-9","article-title":"Treatment of RAF1-related biventricular hypertrophy and double chamber right ventricle by MEK inhibition using trametinib","volume":"92","author":"Krasic","year":"2025","journal-title":"Indian J Pediatr"},{"key":"R16-20251226","doi-asserted-by":"crossref","first-page":"e9164","DOI":"10.1002\/ccr3.9164","article-title":"Trametinib restores the central conducting lymphatic flow in a premature infant with Noonan syndrome","volume":"12","author":"Leenders","year":"2024","journal-title":"Clin Case Rep"},{"key":"R17-20251226","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jpeds.2022.05.030","article-title":"Trametinib for refractory Chylous effusions and systemic complications in children with Noonan syndrome","volume":"248","author":"Nakano","year":"2022","journal-title":"J Pediatr"},{"key":"R18-20251226","first-page":"1342","article-title":"Refractory chylothorax and ventricular hypertrophy treated with trametinib in a patient with Noonan syndrome: 18-month follow-up","volume":"11","author":"Pascarella","year":"2024","journal-title":"Children (Basel)"},{"key":"R19-20251226","doi-asserted-by":"crossref","article-title":"Noonan syndrome: clinical features, diagnosis, and management guidelines","author":"Romano","DOI":"10.1542\/peds.2009-3207"},{"key":"R20-20251226","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.gim.2022.04.004","article-title":"Neurologic and neurodevelopmental complications in cardiofaciocutaneous syndrome are associated with genotype: a multinational cohort study","volume":"24","author":"Pierpont","year":"2022","journal-title":"Genet Med"},{"key":"R21-20251226","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/s41431-024-01643-6","article-title":"Defining the variant-phenotype correlation in patients affected by Noonan syndrome with the RAF1:c.770C>T p.(Ser257Leu) variant","volume":"32","author":"Gazzin","year":"2024","journal-title":"Eur J Hum Genet"},{"key":"R22-20251226","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1161\/CIRCGEN.122.003861","article-title":"Natural history of hypertrophic cardiomyopathy in Noonan syndrome with multiple lentigines","volume":"16","author":"Monda","year":"2023","journal-title":"Circ Genom Precis Med"},{"key":"R23-20251226","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/ajmg.a.36982","article-title":"Rapidly progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome with multiple lentigines: palliative treatment with a rapamycin analog","volume":"167A","author":"Hahn","year":"2015","journal-title":"Am J Med Genet A"},{"key":"R24-20251226","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.tcm.2012.03.006","article-title":"PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots?","volume":"21","author":"Lauriol","year":"2011","journal-title":"Trends Cardiovasc Med"},{"key":"R25-20251226","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ajmg.a.63428","article-title":"Epilepsy in cardiofaciocutaneous syndrome: clinical burden and response to antiseizure medication","volume":"194","author":"Kenney-Jung","year":"2024","journal-title":"Am J Med Genet A"},{"key":"R26-20251226","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/epi4.12864","article-title":"Status epilepticus in BRAF-related cardio-facio-cutaneous syndrome: focus on neuroimaging clues to physiopathology","volume":"9","author":"Musto","year":"2024","journal-title":"Epilepsia Open"},{"key":"R27-20251226","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pediatrneurol.2023.08.019","article-title":"Treatment of refractory epilepsy with MEK inhibitor in patients with RASopathy","volume":"148","author":"D\u2019Onofrio","year":"2023","journal-title":"Pediatr Neurol"},{"key":"R28-20251226","doi-asserted-by":"crossref","first-page":"e70087","DOI":"10.1002\/hbm.70087","article-title":"Elucidating microstructural alterations in neurodevelopmental disorders: application of advanced diffusion-weighted imaging in children with rasopathies","volume":"45","author":"Plank","year":"2024","journal-title":"Hum Brain Mapp"},{"key":"R29-20251226","doi-asserted-by":"crossref","first-page":"fcae274","DOI":"10.1093\/braincomms\/fcae274","article-title":"Impact of pathogenic variants of the Ras-mitogen-activated protein kinase pathway on major white matter tracts in the human brain","volume":"6","author":"Siqueiros-Sanchez","year":"2024","journal-title":"Brain Commun"},{"key":"R30-20251226","first-page":"858","article-title":"Influences of RASopathies on neuroanatomical variation in children","volume":"9","author":"McGhee","year":"2024","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"R31-20251226","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41398-023-02504-4","article-title":"Novel effects of Ras-MAPK pathogenic variants on the developing human brain and their link to gene expression and inhibition abilities","volume":"13","author":"Rai","year":"2023","journal-title":"Transl Psychiatry"},{"key":"R32-20251226","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.3390\/genes14122173","article-title":"Research on the pathogenesis of cognitive and neurofunctional impairments in patients with Noonan syndrome: the role of rat sarcoma-mitogen activated protein kinase signaling pathway gene disturbances","volume":"14","author":"Braun-Walicka","year":"2023","journal-title":"Genes (Basel)"},{"key":"R33-20251226","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/02699206.2023.2298976","article-title":"Language profiles in Noonan Syndrome \u2013 a multiple case study","volume":"38","author":"Selas","year":"2024","journal-title":"Clin Linguist Phon"},{"key":"R34-20251226","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/jir.13247","article-title":"Characterisation of challenging behaviours and associated genetic and neurological features in cardiofaciocutaneous syndrome","volume":"69","author":"Rogers","year":"2025","journal-title":"J Intellect Disabil Res"},{"key":"R35-20251226","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/adc.2006.104547","article-title":"The natural history of Noonan syndrome: a long-term follow-up study","volume":"92","author":"Shaw","year":"2007","journal-title":"Arch Dis Child"},{"key":"R36-20251226","doi-asserted-by":"crossref","first-page":"101355","DOI":"10.1016\/j.gim.2025.101355","article-title":"Longitudinal outcomes in Noonan syndrome","volume":"27","author":"Rippert","year":"2025","journal-title":"Genet Med"},{"key":"R37-20251226","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1136\/adc.67.2.178","article-title":"A clinical study of Noonan syndrome","volume":"67","author":"Sharland","year":"1992","journal-title":"Arch Dis Child"},{"key":"R38-20251226","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13023-023-02818-y","article-title":"The most important problems and needs of RASopathy patients with a Noonan syndrome spectrum disorder","volume":"18","author":"Tiemens","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"R39-20251226","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00431-024-05933-5","article-title":"Do children with a Noonan syndrome-like RASopathy and avoidant\/restrictive food intake disorder benefit from behavioral therapy?","volume":"184","author":"Dumont","year":"2024","journal-title":"Eur J Pediatr"},{"key":"R40-20251226","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s00415-023-12070-w","article-title":"Mutations in PTPN11 could lead to a congenital myasthenic syndrome phenotype: a Noonan syndrome case series","volume":"271","author":"Pugliese","year":"2024","journal-title":"J Neurol"},{"key":"R41-20251226","doi-asserted-by":"crossref","first-page":"e63810","DOI":"10.1002\/ajmg.a.63810","article-title":"Nerve enlargement in patients with Noonan syndrome: a retrospective cohort study","volume":"194","author":"Draaisma","year":"2024","journal-title":"Am J Med Genet A"},{"key":"R42-20251226","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1007\/s00431-023-05045-6","article-title":"Hypertrophic neuropathy: a possible cause of pain in children with Noonan syndrome and related disorders","volume":"182","author":"Draaisma","year":"2023","journal-title":"Eur J Pediatr"},{"key":"R43-20251226","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ajmg.a.63397","article-title":"Prenatal and infantile diagnosis of craniosynostosis in individuals with RASopathies","volume":"194","author":"Serbinski","year":"2024","journal-title":"Am J Med Genet A"},{"key":"R44-20251226","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s12887-024-04827-7","article-title":"Computer-based facial recognition as an assisting diagnostic tool to identify children with Noonan syndrome","volume":"24","author":"Huang","year":"2024","journal-title":"BMC Pediatr"},{"key":"R45-20251226","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41525-025-00512-5","article-title":"Sequencing validates deep learning models for EHR-based detection of Noonan syndrome in pediatric patients","volume":"10","author":"Yang","year":"2025","journal-title":"NPJ Genom Med"},{"key":"R46-20251226","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.gim.2022.08.002","article-title":"Using deep learning and electronic health records to detect Noonan syndrome in pediatric patients","volume":"24","author":"Yang","year":"2022","journal-title":"Genet Med"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T11:00:25Z","timestamp":1766746825000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001524","relation":{},"ISSN":["1531-698X"],"issn-type":[{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]}}}